The survey on cellular and engineered tissue therapies in europe in 2012

Tissue Engineering - Part A

Volumn 21, Issue 1-2, 2015, Pages 1-13

  Martin, Ivan ^a   Ireland, Hilary ^a   Baldomero, Helen ^a   Passweg, Jakob ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELLS; CYTOLOGY; GRAFT VS. HOST REACTIONS; MUSCULOSKELETAL SYSTEM; PATIENT TREATMENT; STEM CELLS; SURVEYS; TISSUE;

ALLOGENEIC CELLS; DERMAL FIBROBLASTS; ENGINEERED TISSUES; EX VIVO EXPANSION; GASTROINTESTINAL DISORDERS; GRAFT VERSUS HOST DISEASE; HEMATOPOIETIC STEM CELLS; NEUROLOGICAL DISORDERS;

SCAFFOLDS (BIOLOGY);

AUTOTRANSPLANTATION; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CARTILAGE CELL; CELL ENGINEERING; CELL EXPANSION; CELL SELECTION; CELL THERAPY; CELLS BY BODY ANATOMY; EUROPE; EX VIVO STUDY; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; KERATINOCYTE; MESENCHYMAL STEM CELL; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SKIN FIBROBLAST; TISSUE ENGINEERING; TRANSPLANTATION; CELL TRANSPLANTATION; DONOR; GEOGRAPHY; HEALTH CARE SURVEY; RESEARCH; STATISTICS AND NUMERICAL DATA;

CELL TRANSPLANTATION; EUROPE; GEOGRAPHY; HEALTH CARE SURVEYS; HUMANS; RESEARCH REPORT; TISSUE DONORS; TISSUE ENGINEERING;

EID: 84921391940     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2014.0515     Document Type: Review

References (30)

1. Birchall, M.A., and Seifalian, A.M. Tissue engineering's green shoots of disruptive innovation. Lancet 384, 288, 2014.
2. Pirnay, J.-P., Vanderkelen, A., de Vos, D., Draye, J.-P., Rose, T., Ceulemans, C., Ectors, N., Hays, I., Jennes, S., and Verbeken, G. Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems. Cell Tissue Bank 14, 525, 2013.
3. Martin, I., Baldomero, H., Tyndall, A., Niederwieser, D., and Gratwohl, A. A survey on cellular and engineered tissue therapies in Europe in 2008. Tissue Eng Part A 16, 2419, 2010.
4. Martin, I., Baldomero, H., Bocelli-Tyndall, C, Slaper-Cortenbach, I., Passweg, J., and Tyndall, A. The survey on cellular and engineered tissue therapies in Europe in 2009. Tissue Eng Part A 17, 2221, 2011.
5. Martin, I., Baldomero, H., Bocelli-Tyndall, C, Passweg, J., Saris, D., and Tyndall, A. The survey on cellular and engineered tissue therapies in Europe in 2010. Tissue Eng Part A 18, 2268, 2012.
6. Martin, I., Baldomero, H., Bocelli-Tyndall, C, Emmert, M.Y., Hoerstrup, S.P., Ireland, H., Passweg, J., and Tyndall, A. The survey on cellular and engineered tissue therapies in Europe in 2011. Tissue Eng Part A 20, 842, 2014.
7. Lin, Y., and Hogan, W.J. Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease. Adv Hematol 2011, 427863, 2011.
8. Osiris Press Release via Business Wire. Osiris Therapeutics announces preliminary results for Prochymal" phase III GvHD trials. 8 September 2014.
9. TrialsUnited.com. Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease. ClinicalTrials.gov Identifier: NCT00366145, 2013.
10. US National Institutes of Health. Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease. ClinicalTrials.gov Identifier: NCT00366145, 2011.
11. Mesoblast Ltd. News Release, Reported via Globe News-wire. Mesoblast acquires Osiris' culture expanded stem cell therapeutic business. 10 October 2013.
12. Chen, G.L., Paplham, P., and McCarthy, PL. Re-mestemcel-L for acute graft-versus-host disease therapy. Expert Opin Biol Ther 14, 261, 2014.
13. Galipeau, J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 15, 2, 2013.
14. HOVON Studies SCT. Stem cell transplantation and cellular therapies. HOVON 112 MSC, 2013.
15. Werner, S., Krieg, T., and Smola, H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol 127, 998, 2007.
16. Wojtowicz, A.M., Oliveira, S., Carlson, M.W., Zawadzka, A., Rousseau, C.F., and Baksh, D. The importance of both fibroblasts and keratinocytes in abilayered living cellular construct used in wound healing. Wound Repair Regen 22, 246, 2014.
17. Varkey, M., Ding, J., and Tredget, E.E. Superficial dermal fibroblasts enhance basement membrane and epidermal barrier formation in tissue-engineered skin: implications for treatment of skin basement membrane disorders. Tissue Eng Part A 20, 540, 2014.
18. Fu, X., and Li, H. Mesenchymal stem cells and skin wound repair and regeneration: possibilities and questions. Cell Tissue Res 335, 317, 2009.
19. Walter, M.N., Wright, K.T., Fuller, H.R., MacNeil, S., and Johnson, W.E. Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays. Exp Cell Res 316, 1271, 2010.
20. US National Institutes of Health. Dendritic cell vaccination for patients with solid tumors. ClinicalTrials.gov Identifier: NCT01291420, 2013.
21. US National Institutes of Health. Phase II study with hil-tonol and dendritic cells in solid tumors. ClinicalTrials.gov Identifier: NCT01734564, 2013.
22. US National Institutes of Health. ADIPOA-clinical study. ClinicalTrials.gov Identifier: NCT01585857, 2014.
23. Madry, H., and Cucchiarini, M. Advances and challenges in gene-based approaches for osteoarthritis. J Gene Med 15, 343, 2013.
24. Evans, C.H., Ghivizzani, S.C., and Robbins, P.D. Arthritis gene therapy and its tortuous path into the clinic. Transl Res 161, 205, 2013.
25. Almqvist, K.F., Dhollander, A.A., Verdonk, P.C., Forsyth, R., Verdonk, R., and Verbruggen, G. Treatment of cartilage defects in the knee using alginate beads containing human mature allogeneic chondrocytes. Am J Sports Med 37, 1920, 2009.
26. Evans, C.H., Kraus, V.B., and Setton, L.A. Progress in intra-Articular therapy. Nat Rev Rheumatol 10, 11, 2014.
27. US National Institutes of Health. Reparation of cartilage injuries in the human knee by implantation of fresh human allogeneic chondrocytes. ClinicalTrials.gov Identifier: NCT00263432, 2013.
28. European Medicines Agency. Guideline on human cell-based medicinal products EMEA/CHMP/410869/2006. www.ema.europa.eu/pdfs/human/cpwp/41086906enfin.pdf, 2008.
29. The Committee for Advanced Therapies (CAT) and the CAT Scientific Secretariat. Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 9, 195, 2010.
30. Martin, I., Simmons, P.J., and Williams, D.F. Manufacturing challenges in regenerative medicine. Sci Transl Med 6, 232fs16, 2014.